Disability

Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD

Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment…

2 years ago

ReWalk Robotics to Report Fourth Quarter and Fiscal Year-End 2022 Financial Results on February 23, 2023

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Feb. 16, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”…

2 years ago

Acasti Pharma Reports Third Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc.…

2 years ago

Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®

In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to…

2 years ago

Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the…

2 years ago

AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Study designed to optimize treatment regimen and evaluate efficacy over six-month dosing period Initial results expected in second half of…

2 years ago

MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director

Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA,…

2 years ago